Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
3 competitors in Acute Myeloid Leukemia
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Daurismo
Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy.
Vaccines, Pneumococcal
Renal Transplantation
Diabetes Mellitus
Major Depressive Disorder
Complicated Intra-abdominal Infections